Genprex (GNPX)

• Market cap: $5M
• 1 day: -6.04%
• 5 days: -29.48%
• 1 month: -43.2%
• 3 months: -77.91%
• 6 months: -81.19%
• Year to date: -74.46%
• 1 year: -97.03%
• 5 years: -99.99%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Employees: 13